The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Post-transplant cyclophosphamide versus standard GvHD prophylaxis after alloSCT for AML & MDS
Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discusses a study which evaluated risk of relapse and survival outcomes of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) receiving post-transplant cyclophosphamide versus standard graft-versus-host disease (GvHD) prophylaxis. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Medexus Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CareDX Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
